A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis Clinical Trial

Official title:

An Open-label Phase 1b Study Assessing the Safety, Tolerability and Preliminary Diagnostic Performance of a Radioactive Imaging Agent, NDX-3315 and NDX-3324, in Healthy Adult Participants and Patients With Eosinophilic Esophagitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05757856
• Other study ID #: NDX-3315-1001
• Status: Recruiting
• Phase: Phase 1
• Start date: January 20, 2023
• Est. completion date: September 2024

Study information

• Verified date: January 2024
• Source: NexEos Diagnostics, Inc.
• Contact: NDX-3315-1001 Study Team
• Phone: (484) 267-3909
• Email: clinicaltrials.gov[@]nexeosdx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open-label phase 1b study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).

Description:

This study is a multi-site, Phase 1b, open-label study of orally administered NDX-3315 or NDX-3324 and esophageal imaging in healthy participants and participants with EoE.

Study details include:

• The study duration or period will be up to around 10 weeks.

• Participants will receive either one or two doses of NDX-3315 or NDX-3324 depending on their assigned regimen arm. EoE participants will receive two doses; healthy participants will receive one dose. There will be a SPECT/CT scan performed at each dose.

• The visit frequency will be three site visits for healthy participants and four site visits for EoE participants followed by one follow-up phone call visit within the study period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy Participants:

• Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) assessment.

• EoE Participants:

• Documented diagnosis of EoE (based on prior endoscopy with biopsies showing eosinophils =15 / HPF); AND

• History (by patient report) of recurrent dysphagia and/or other related EoE symptoms (with intake of solids off anti-inflammatory therapy) prior to screening; dysphagia is defined as trouble swallowing solid food, or having solid food stuck, by patient report.

Exclusion Criteria:

• Medical Conditions:

• Participant with presence of any other disease of the GI tract, including cancer, autoimmune esophageal disease, GERD which is symptomatic or uncontrolled, Barrett's esophagus, eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory bowel disease; or celiac disease. Known motility disorder of esophagus; achalasia or suspicion thereof.

• Sleep apnea, if considered by the investigator a concern for the endoscopic procedure.

• History of recurrent aspiration pneumonia.

• History of bleeding disorders, liver cirrhosis or esophageal varices.

• A current malignancy or previous history of cancer in remission for less than 5 years prior to Screening (participants will not be excluded if they had localized carcinoma of the skin that was resected for cure).

• Participant with a Body Mass Index >40 m2/kg or inability to undergo a CT (or SPECT scan) due to weight limitations.

• Participant is pregnant or nursing.

• Prior/Concomitant Therapy:

• Participant who is on anticoagulation therapy that, in the investigator or Medical Monitor's opinion, cannot safely come off medication.

• Use of chronic aspirin (with the exception of low-dose aspirin as long as the dose remains stable and not increased while on study), nonsteroidal agents, or anti-coagulants within 2 weeks prior to screening.

• Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 6 weeks prior to Screening visit.

• Participant is being treated with systemic immunosuppression, carafate (sucralfate), or investigational agent of any kind within less than 3 months or 5 half-lives, whichever is longer, prior to Screening visit (this also includes investigational formulations of marketed products).

• Diagnostic Assessments:

• Evidence of clinically significant abnormality in the hematological and biochemical assessments at Screening Visit, specifically: International Normalized Ratio (INR) >1.4; platelet count <80,000/µL and creatinine level >2 mg/dL.

• ECG: QTcF =450 msec for males and QTcF =470 msec for females at the time of screening.

• Other Exclusion Criteria:

• Any condition that would not permit adequate biopsies of the esophagus (e.g., esophageal varices, significant stricture precluding passage of a 9 mm endoscope, known allergy to sedative used for endoscopy).

• Healthy Participants Only: A history or current diagnosis of allergic diseases (Should be discussed with Medical Monitor and PI to decide whether exclusionary), autoimmune disease, chronic rhinosinusitis or serum immunoglobulin E (IgE) level =100 kU/L. On any medications including NSAIDS and any over the counter (OTC) medications unless it is birth control or acne medications with the exception of Accutane, or if deemed acceptable to use by Medical Monitor and PI.

Related Conditions & MeSH terms

• Eosinophilic Esophagitis
• Esophagitis

Intervention

Drug:
• NDX-3315 and NDX-3324
Oral solution

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
NexEos Diagnostics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of all participants with AEs following administration of NDX-3315 and NDX-3324	An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product and that does not necessarily have causal relationship with this treatment.	From start of study drug administration up to End of Study (EOS) ( Up to 3 Weeks)
Secondary	Partial Thromboplastin Time (PTT) as marker of pharmacodynamics (PD)	Blood samples will be collected to measure Partial Thromboplastin Time (PTT), which is a blood test that looks at how long it takes for blood to clot.	Baseline, 2 hours post-dose (Up to 1 Week)
Secondary	Radioactivity of blood collected from participants exposed to NDX-3315 and NDX-3324.	Blood samples will be collected to measure radioactivity as counts per minute(cpm) and disintegrations per minute(dpm).	2.5 hours post-dose (Up to 1 Week)
Secondary	Visual ratings of SPECT images	A blinded central reviewer will review SPECT images for uptake of NDX-3315 or NDX-3324 per region of interest(ROI) of the esophagus using a 5-point scale (0= no uptake to 4 = uptake similar to bowel), with 4 being the worst result.	Up to 45 minutes after dose
Secondary	Absolute quantification of SPECT imaging	SPECT images will be analyzed for radioactive per region of interest(ROI) of the esophagus.	Up to 45 minutes after dose
Secondary	Peak eosinophil counts per high-power field (HPF)	A blinded pathologist will perform peak eosinophil counts per high-power field (HPF) on biopsy specimens of the esophagus.	Up to 10 days after last dose
Secondary	Deposition of eMBP1	A blinded immunostaining analyst will perform analysis of deposition of Eosinophil Major Basic Protein 1 (eMBP1) via immunostaining of biopsy specimens of the esophagus.	Up to 10 days after last dose
Secondary	EoE Endoscopic Reference Score (EREFS)	The EoE-EREFS (Edema, Rings, Furrows, Exudates, Strictures) scores are used to measure the endoscopically identified EoE esophageal mucosal characteristics. The evaluation includes stricture (if applicable); exudates (absent, mild, severe); furrows (absent, present); edema (absent, present); crepe paper esophagus (absent, present), and overall general appearance incorporating all endoscopically-identified EoE findings (e.g., fixed rings, strictures, whitish exudates, furrowing, edema, and crepe paper mucosa). The EoE -EREFS score being used in this study has a range from 0-11, with 11 being the worst result.	Up to 10 days after last dose
Secondary	EoE Symptom Collection Questionnaire	A questionnaire will be used to collect study participant symptoms such as severity of EoE dysphasia as well as concerns about pain. Answers will have corresponding score ranging from 1-18, with 18 being the worst result.	Baseline (All participants), Day 1 (EoE participants only)